Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

Background: Several monoclonal antibodies (mAb) are being evaluated as treatment
options for the current 2014 Ebola outbreak. But they were derived from and tested for …

The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …

Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and
local economies. Effective vaccines and treatments against EBOV are therefore needed to …

Ebola viruses can cause severe hemorrhagic fever in humans and nonhuman primates with
fatality rates up to 90%, and are identified as biosafety level 4 pathogens and CDC Category …

The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has
highlighted the need for effective therapeutics against filoviruses. Monoclonal antibody …

Out of an estimated 31,100 cases since their discovery in 1976, ebolaviruses have caused
approximately 13,000 deaths. The vast majority (∼ 11,000) of these occurred during the …

Passive administration of monoclonal antibodies (mAbs) is a promising therapeutic
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …

This review describes the history of Ebola monoclonal antibody (mAb) development leading
up to the recent severe Ebola outbreak in West Africa. The Ebola virus has presented …

Cocktails of monoclonal antibodies (MAbs) that target the surface glycoprotein (GP) of Ebola
virus (EBOV) are effective in nonhuman primate models and have been used under …